Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide for prevention of smoking relapse in adults
CTR20255150Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of brenipatide in nicotine dependence, sponsored by Eli Lilly and Company. Started Dec 2025; status: active.
02
Drugs
brenipatide
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on CTR20255150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255150.